par Callie Weber | Sep 17, 2026 | Access to Care, NCD Partnerships, Actualités
Nigeria’s National Institute for Cancer Research and Treatment (NICRAT) has joined Innovative Medicines Access Programme (IMAP), following the signing of a Letter of Agreement with Bristol Myers Squibb (BMS) in August 2026. The agreement was signed in the presence of...
par E | Avr 9, 2026 | Access to Care, NCD Partnerships, Actualités
As a member of the UICC-led ATOM Coalition, NCDconnect has partnered with Bristol Myers Squibb (BMS) and Coalition partners to help implement BMS’ Innovative Medicines Access Program (IMAP). NCDconnect plays a critical role in this by designing country-specific...
par E | Juin 26, 2025 | Access to Care, NCD Partnerships, Actualités
In many low- and middle-income countries (LMICs), a childhood cancer diagnosis often comes with limited access to timely treatment, essential medicines, and consistent care. That’s why earlier this year, NCDconnect—through IDA Foundation—joined the Access Cancer...
par E | Mar 13, 2025 | Access to Care, NCD Partnerships, Actualités
A new article in The Lancet Oncology1 highlights the urgent need for sustainable solutions to improve cancer treatment access in low- and middle-income countries (LMICs). Authored by ATOM Coalition experts, the article outlines key barriers to medicine availability...
par E | Déc 17, 2024 | NCD Case Studies, NCD Partnerships, Actualités
Following the agreement on a new licensing model between the Medicines Patent Pool (MPP) & Novartis in collaboration with the ATOM Coalition, generic, quality-assured nilotinib is now available on NCDconnect! This initiative is crucial in making lifesaving...
par Callie Weber | Avr 15, 2024 | Access to Care, NCD Partnerships, Actualités
IDA Foundation and FIND have joined forces to help address the challenges of availability, affordability, and optimal use of diagnostics for Noncommunicable Diseases (NCDs) in low- and middle-income countries (LMICs). IDA Foundation and FIND Partner to Deliver NCD...
